Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Alnylam Pharmaceuticals Insider Amy W. Schulman Buys $300K of Stock
Amy W. Schulman bought 1,910 shares of Alnylam Pharmaceuticals, Inc. at $156.82 a share, worth $300K in total on Nov 9, 2026. Shares held after the trade: 25,959 (+7.9%).
Applied Optoelectronics CFO Stefan J. Murry Sells $195K of Stock
Stefan J. Murry, CFO, sold 4,000 shares of Applied Optoelectronics, Inc. at $48.83 a share, worth $195K in total on Nov 10, 2026. Shares held after the trade: 353,223 (-1.1%).
Pluri Inc. reported a significant increase in net loss to $15.39 million for the quarter ended September 30, 2026, primarily driven by a $10.9 million charge for acquired in-process research and development related to the Fishway Transaction. Despite the loss, revenues grew to $759,000 compared to $316,000 in the prior year, and the company successfully raised capital through share issuances and a SAFE agreement.
SOPHiA Genetics Executive Chairman Jurgi Camblong Sells $65.9K of Stock
Jurgi Camblong, Executive Chairman, sold 8,500 shares of SOPHiA Genetics SA at $7.76 a share, worth $65.9K in total on Nov 10, 2026. Shares held after the trade: 3,378,650 (-0.3%).
Avalanche Treasury Corporation reported a net loss of $16.8 million for the nine months ended September 30, 2026, despite a profitable third quarter with net income of $54.6 million driven by changes in the fair value of digital assets. The company's balance sheet shows significant holdings in AVAX and USDC, with total assets decreasing from $190.9 million at year-end 2025 to $151.9 million.
SOPHiA Genetics Insider Kathy L. Hibbs Sells $48.5K of Stock
Kathy L. Hibbs sold 6,250 shares of SOPHiA Genetics SA at $7.76 a share, worth $48.5K in total on Nov 10, 2026. Shares held after the trade: 90,742 (-6.4%).
Frontdoor, Inc. has appointed Mary Hopkins as Vice President, Controller and Chief Accounting Officer, effective December 14, 2026. Her compensation package includes an annual base salary of $415,000, a 50% target bonus, a $250,000 sign-on cash bonus, and a $250,000 sign-on equity grant in restricted stock units.
Atlantic Acquisition Corp I (formerly JAB Acquisition Corp I) held an Extraordinary General Meeting where shareholders approved a formal name change and the adoption of amended and restated Memorandum and Articles of Association. The name change became effective on November 9, 2026, and the company's trading symbols on Nasdaq remain ATLQ, ATLQU, ATLQW, and ATLQR.
TheRealReal CFO Gopal Ajay Madan Sells $1.04M of Stock
Gopal Ajay Madan, CFO, sold 71,027 shares of TheRealReal, Inc. at $14.65 a share, worth $1.04M in total on Nov 11, 2026. Shares held after the trade: 1,037,833 (-6.4%).
Bank of the James Financial Group reported net income of $9.34 million for the first nine months of 2026, a significant increase from $6.30 million in the same period of 2025, driven by higher net interest income. Total assets grew to $1.06 billion, though stockholders' equity slightly decreased to $78.4 million due to an increase in accumulated other comprehensive loss from unrealized losses on available-for-sale securities.
SOPHiA Genetics CLO Well Daan Van Sells $10.5K of Stock
Well Daan Van, CLO, sold 1,411 shares of SOPHiA Genetics SA at $7.44 a share, worth $10.5K in total on Nov 9, 2026. Shares held after the trade: 331,305 (-0.4%).
Noble Roman's reported total revenue of $11.27 million for the nine months ended September 30, 2026, a slight increase from the prior year, though net income decreased from $882,839 to $396,072. The company successfully refinanced its debt, moving the majority of its senior loan obligations from current to long-term liabilities.
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.
Term
FY2026
“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”
Christopher Anzalone, Ph.D., President and CEO
“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”
KIDZ AI Inc. reported a significant net loss of $7.34 million for the nine months ended September 30, 2026, compared to a $1.64 million loss in the prior year, driven by a $3.38 million fair value loss on crypto assets. Despite the loss, the company significantly strengthened its balance sheet through $10.74 million in private placement capital contributions and the conversion of $9.46 million in debt into equity.
Hartford Creative Group reported total revenues of $2,744,029 for fiscal 2026, a 35% increase driven by its advertising agency business, though net income fell 42% to $641,767 due to a significant credit loss expense and higher income taxes. The company is pivoting toward a mini-drama platform (YYYS App) and is pursuing an uplisting to the Nasdaq Capital Market to fund its estimated $2.0 million in upcoming capital requirements.
Drilling Tools International Director Jack D. Furst Buys $23.8K of Stock
Jack D. Furst, Director, bought 14,441 shares of Drilling Tools International Corp at $1.65 a share, worth $23.8K in total on Nov 11, 2026. Shares held after the trade: 77,920 (+22.7%).
AXT, Inc. reported a significant revenue increase to $73.4 million for the third quarter of 2026, up from $28.0 million in the prior year, driven by improved gross margins and operational performance. The company swung to a net income of $25.7 million for the quarter compared to a net loss of $1.9 million in 2025, while its cash position strengthened substantially to $485.5 million following a major common stock issuance.
For the nine months ended September 30, 2026, Akari Therapeutics reported a net loss of $24.1 million, significantly higher than the $12.0 million loss in the prior year period, primarily driven by $12.1 million in impairment losses on goodwill and intangible assets. The company maintained a cash balance of $5.7 million and saw its total shareholders' equity decrease from $28.3 million to $17.5 million during the period.
Intellinetics, Inc. reported a decrease in total assets from $17.3 million at year-end 2025 to $16.7 million as of September 30, 2026. The company's accumulated deficit increased to $26.0 million, while deferred revenues grew significantly to $4.1 million, reflecting shifts in its software-as-a-service and recurring revenue model.
EagleRock Land, LLC is an emerging growth company focused on surface, resource, and water infrastructure assets in the Permian Basin. The filing highlights its recent initial public offering in May 2026 and outlines key operational risks including customer concentration, commodity price volatility, and reliance on surface use agreements.
Yale Transaction Finders, Inc. is a shell company with no revenue, reporting a net loss of $23,521 for the nine months ended September 30, 2026. The company faces substantial doubt about its ability to continue as a going concern, characterized by an accumulated deficit of $1,421,109 and reliance on related-party financing.
TheRealReal CAO Steve Ming Lo Sells $299K of Stock
Steve Ming Lo, CAO, sold 20,070 shares of TheRealReal, Inc. at $14.90 a share, worth $299K in total on Nov 10, 2026. Shares held after the trade: 156,840 (-11.3%).
SELLAS Life Sciences Group reported a net loss of $10.1 million for the third quarter of 2026, compared to $6.8 million in the prior year period, driven by increased research and development expenses. The company strengthened its balance sheet significantly, ending the period with $134.7 million in cash and cash equivalents following substantial warrant exercises during the nine months ended September 30, 2026.
Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.
“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
Amylyx Pharmaceuticals CFO James M. Frates Sells $1.21M of Stock
James M. Frates, CFO, sold 40,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.97 a share (average $30.19) in 4 transactions, worth $1.21M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 233,625 (-3.0%).
Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen Sells $2.98M of Stock
Joshua B. Cohen, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,123 (-1.7%).
Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells $2.98M of Stock
Justin B. Klee, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,056 (-1.7%).
Stone Point Credit Corp reported a net increase in net assets from operations of $60.2 million for the nine months ended September 30, 2026, down from $95.2 million in the prior year period. The decrease was primarily driven by $29.6 million in net unrealized depreciation, while net investment income remained relatively stable at $89.3 million.
Federal Home Loan Bank of Topeka $3.29B Debt Financing with Office of Finance
Federal Home Loan Bank of Topeka issued $3.285 billion in consolidated obligation bonds and notes between November 9 and November 10, 2026. These debt securities are the joint and several obligations of the eleven Federal Home Loan Banks and are used to fund the bank's operations. The issuances include both fixed-rate and variable-rate instruments with maturities ranging from March 2027 to November 2028.